Artiva Biotherapeutics, Inc. (ARTV), a clinical-stage biotechnology company, on Friday announced the pricing of an underwritten offering of stock and pre-funded warrants.
The offering consists of 23.87 million shares of stock priced at $11.52 per share and pre-funded warrants to purchase 2.17 million shares at a purchase price of $11.5199 per warrant.
The transaction is expected to close on or about May 11.
The offering is expected to raise approximately $300 million in gross proceeds.
In the pre-market trading, Artiva Biotherapeutics is 17.41% higher at $14.65 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.